STAGE IV LUNG CANCER AJCC V8
Clinical trials for STAGE IV LUNG CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV LUNG CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV LUNG CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New targeted therapy shows promise for rare lung cancer subtype
Disease control OngoingThis study tests a drug called selpercatinib (LOXO-292) in people with advanced non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug works by blocking signals that help cancer cells grow. About 124 participants will receive the treatment to …
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 01, 2026 15:40 UTC
-
Two-Drug combo shows promise against tough cancers
Disease control OngoingThis early-phase trial tests a new combination of two drugs—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Sonidegib blocks certain enzymes that help cancer gr…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 01, 2026 15:38 UTC
-
New DNA vaccine aims to train immune system against lung cancer
Disease control OngoingThis study tests a DNA vaccine called STEMVAC in people with stage IV non-small cell lung cancer. The vaccine gives the body instructions to make parts of five proteins found on lung cancer cells, helping the immune system recognize and attack them. The trial includes 5 participa…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 01, 2026 15:38 UTC
-
One-and-Done radiation: could a single dose beat weeks of treatment for lung cancer?
Disease control OngoingThis early-stage study tests whether giving a single, precise dose of radiation after surgery for non-small cell lung cancer is safe and feasible. Standard radiation requires many small doses over weeks, which can damage healthy lung tissue. The study involves 50 patients who had…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 01, 2026 15:28 UTC
-
New cocktail targets tough lung cancer: early trial shows promise
Disease control OngoingThis early-phase study tests a combination of four drugs (ensartinib, carboplatin, pemetrexed, and bevacizumab) in people with advanced ALK-positive non-small cell lung cancer that has spread or returned. The goal is to find the best dose and check for side effects. About 12 part…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:28 UTC
-
New drug combo targets tough lung cancer in small early trial
Disease control OngoingThis early-phase study tests a combination of two drugs, brigatinib and bevacizumab, in about 5 people with a specific type of advanced lung cancer (ALK-positive) that has continued to grow despite prior treatment. The main goals are to find the best dose and check for side effec…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
Triple threat: new combo aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis study tests a combination of three drugs—docetaxel (chemo), ramucirumab (blocks blood vessel growth), and pembrolizumab (immunotherapy)—in 30 adults with advanced non-small cell lung cancer that worsened after standard treatments. The goal is to see if this triple therapy is…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New drug combo shows promise in Tough-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug (BAY 1895344) combined with standard chemotherapy in people with advanced solid tumors, especially bladder cancer. The goal is to find the best dose and see if the combination is safe and tolerable. About 74 participants will receive the dr…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Experimental combo shows promise for tough lung cancers
Disease control OngoingThis study tests a new drug, pevonedistat, combined with standard chemotherapy (carboplatin and paclitaxel) in people with advanced non-small cell lung cancer that has already been treated with immunotherapy. The goal is to see if this combination can shrink tumors or slow cancer…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New drug combo targets resistant lung cancer in early trial
Disease control OngoingThis early-phase trial tests the safety and best dose of combining two drugs—osimertinib and necitumumab—in people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. About 138 adults with stage IV or recurrent lung cancer will take pa…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Could adding surgery or radiation to immunotherapy boost survival in advanced lung cancer?
Disease control OngoingThis study looks at whether adding local treatments like surgery or radiation to a combination of two immunotherapy drugs (nivolumab and ipilimumab) helps people with stage IV non-small cell lung cancer live longer. About 339 participants will receive the immunotherapy drugs alon…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug (M6620) combined with a standard chemotherapy (irinotecan) in people with advanced solid tumors that have spread or can't be removed. The main goal is to find the safest dose and understand side effects. About 66 adults with certain cancers…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New hope for lung cancer patients with brain tumors: drug combo shows promise
Disease control OngoingThis study looked at whether adding bevacizumab to osimertinib helps control EGFR-mutant lung cancer that has spread to the brain. About 5 adults with this condition took part. The goal was to see if the combination slows cancer growth better than osimertinib alone.
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
New targeted drug shows promise for Hard-to-Treat lung cancer
Disease control OngoingThis study tests a drug called AMG 510 in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The drug targets this change to stop cancer growth. About 116 participants will receive the treatment to see if it shrinks tumors and how safe it is.
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
New drug duo takes on tough lung cancer
Disease control OngoingThis early-stage trial tests the safety and best dose of a new drug called minnelide when given with the standard drug osimertinib for people with advanced non-small cell lung cancer that has an EGFR mutation. The study involves about 8 adults whose cancer has spread or cannot be…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
Heat vs. scalpel: new study tests which lung tumor treatment works best
Disease control OngoingThis study compares two treatments for lung tumors: microwave ablation (using heat to kill cancer cells) and surgical wedge resection (removing a small piece of lung). It includes 74 adults with non-small cell lung cancer, sarcoma, or colorectal cancer that has spread to the lung…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
New combo therapy aims to outdo chemo for advanced lung cancer patients
Disease control OngoingThis phase 3 trial tests whether a combination of two drugs (ramucirumab and pembrolizumab) works better than standard chemotherapy for people with stage IV or recurrent non-small cell lung cancer who have already been treated with immunotherapy. About 838 participants will be ra…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
New online therapy aims to ease emotional burden for women fighting lung cancer
Symptom relief OngoingThis study tests an online program designed to improve social well-being and emotional support for women with non-small cell lung cancer. About 70 women currently receiving treatment will practice mindfulness, compassion, and emotional processing techniques. The goal is to see if…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Apr 30, 2026 15:49 UTC
-
Nurse-Led program aims to ease fear in advanced cancer patients
Symptom relief OngoingThis study tests a nurse-led program designed to help people with advanced lung or gynecologic cancer cope with worries and fears about their disease progressing. About 42 participants will try the program, which includes home practice activities, to see if it is practical and he…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Apr 30, 2026 15:49 UTC
-
Experimental drug combo targets brain tumors from lung cancer
Symptom relief OngoingThis early-phase trial is testing the safety and best dose of a drug called berzosertib when given together with whole brain radiation therapy. It includes 15 adults with lung cancer that has spread to the brain. The goal is to find out if adding the drug to radiation is safe and…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Apr 29, 2026 15:02 UTC
-
New hope for cancer patients losing appetite: drug shows promise in early trial
Symptom relief OngoingThis study looks at whether a drug called anamorelin can help improve appetite and stop weight loss in people with advanced non-small cell lung cancer who have lost their appetite and weight. About 25 participants will take either the drug or a placebo daily and share their exper…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Apr 28, 2026 13:02 UTC
-
Video boosts cancer Patients' genetic test Know-How
Knowledge-focused OngoingThis study tests whether watching a short video helps people with metastatic cancer understand what tumor genomic testing is and why it matters. About 243 adults with advanced cancer will watch the video and answer questions before and after. The goal is to see if the video impro…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:48 UTC
-
Blood test may help cancer patients avoid nerve damage from chemo
Knowledge-focused TerminatedThis study looks at whether doctors can consistently measure the amount of paclitaxel (a chemotherapy drug) in the blood of cancer patients. The goal is to see if this information can help adjust doses to kill cancer while reducing nerve damage, a common side effect. About 22 adu…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Apr 28, 2026 13:02 UTC